Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection

Derseree Archary; Rong Rong; Michelle L. Gordon; Saikat Boliar; Maphuti Madiga; Elin S. Gray; Anne Sophie Dugast; Tandile Hermanus; Philip J.R. Goulder; Hoosen M. Coovadia; Lise Werner; Lynn Morris; Galit Alter; Cynthia A. Derdeyn; Thumbi Ndung'u

doi:10.1016/j.virol.2012.08.033

Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection

Derseree Archary, Rong Rong, Michelle L. Gordon, Saikat Boliar, Maphuti Madiga, Elin S. Gray, Anne Sophie Dugast, Tandile Hermanus, Philip J.R. Goulder, Hoosen M. Coovadia, Lise Werner, Lynn Morris, Galit Alter, Cynthia A. Derdeyn, Thumbi Ndung'u^*

^*Corresponding author for this work

Department of Biosciences and Bioinformatics

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG-FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb (p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression.

Original language	English
Pages (from-to)	410-420
Number of pages	11
Journal	Virology
Volume	433
Issue number	2
DOIs	https://doi.org/10.1016/j.virol.2012.08.033
Publication status	Published - 25 Nov 2012

Keywords

Binding antibodies
Chronic infection
HIV-1 subtype C
Neutralizing antibodies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.virol.2012.08.033

Cite this

Archary, D., Rong, R., Gordon, M. L., Boliar, S., Madiga, M., Gray, E. S., Dugast, A. S., Hermanus, T., Goulder, P. J. R., Coovadia, H. M., Werner, L., Morris, L., Alter, G., Derdeyn, C. A., & Ndung'u, T. (2012). Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology, 433(2), 410-420. https://doi.org/10.1016/j.virol.2012.08.033

@article{0dd953c4175845138358b338e32db248,

title = "Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection",

abstract = "Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG-FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb (p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression.",

keywords = "Binding antibodies, Chronic infection, HIV-1 subtype C, Neutralizing antibodies",

author = "Derseree Archary and Rong Rong and Gordon, {Michelle L.} and Saikat Boliar and Maphuti Madiga and Gray, {Elin S.} and Dugast, {Anne Sophie} and Tandile Hermanus and Goulder, {Philip J.R.} and Coovadia, {Hoosen M.} and Lise Werner and Lynn Morris and Galit Alter and Derdeyn, {Cynthia A.} and Thumbi Ndung'u",

note = "Funding Information: This work was supported by the Howard Hughes Medical Institute, the Hasso Plattner Foundation and the South African Department of Science and Technology/National Research Foundation Research Chair Initiative . D.A. was supported by the Columbia University-Southern African Fogarty AIDS International Training and Research Program funded by the Fogarty International Center, NIH (grant #D43TW00231 ) and NIH R01 AI-58706 to C.A.D.",

year = "2012",

month = nov,

day = "25",

doi = "10.1016/j.virol.2012.08.033",

language = "English",

volume = "433",

pages = "410--420",

journal = "Virology",

issn = "0042-6822",

number = "2",

}

Archary, D, Rong, R, Gordon, ML, Boliar, S, Madiga, M, Gray, ES, Dugast, AS, Hermanus, T, Goulder, PJR, Coovadia, HM, Werner, L, Morris, L, Alter, G, Derdeyn, CA & Ndung'u, T 2012, 'Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection', Virology, vol. 433, no. 2, pp. 410-420. https://doi.org/10.1016/j.virol.2012.08.033

TY - JOUR

T1 - Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection

AU - Archary, Derseree

AU - Rong, Rong

AU - Gordon, Michelle L.

AU - Boliar, Saikat

AU - Madiga, Maphuti

AU - Gray, Elin S.

AU - Dugast, Anne Sophie

AU - Hermanus, Tandile

AU - Goulder, Philip J.R.

AU - Coovadia, Hoosen M.

AU - Werner, Lise

AU - Morris, Lynn

AU - Alter, Galit

AU - Derdeyn, Cynthia A.

AU - Ndung'u, Thumbi

N1 - Funding Information: This work was supported by the Howard Hughes Medical Institute, the Hasso Plattner Foundation and the South African Department of Science and Technology/National Research Foundation Research Chair Initiative . D.A. was supported by the Columbia University-Southern African Fogarty AIDS International Training and Research Program funded by the Fogarty International Center, NIH (grant #D43TW00231 ) and NIH R01 AI-58706 to C.A.D.

PY - 2012/11/25

Y1 - 2012/11/25

N2 - Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG-FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb (p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression.

AB - Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG-FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb (p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression.

KW - Binding antibodies

KW - Chronic infection

KW - HIV-1 subtype C

KW - Neutralizing antibodies

UR - http://www.scopus.com/inward/record.url?scp=84867193794&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2012.08.033

DO - 10.1016/j.virol.2012.08.033

M3 - Article

C2 - 22995189

AN - SCOPUS:84867193794

SN - 0042-6822

VL - 433

SP - 410

EP - 420

JO - Virology

JF - Virology

IS - 2

ER -

Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this